Elixir Clinical Research recently announced that Dr. Tao Wang, with over 17 years of rich experience in the field of drug development, has officially joined the company as Vice General Manager of Department of Data Science and Pharmacovigilance and Head of the Statistics Center. Dr. Tao Wang will be responsible for the expansion and management of the company's Statistics Center after he joins Elixir Clinical Research. With a focus on scientific leadership and innovation empowerment, he aims to transform the Data Science and Statistics Center of Elixir Clinical Research into a professional and efficient team which is dynamic, innovative, and continuously progressing.

Dr. Tao Wang

Dr. Tao Wang successively studied at the School of Public Health at Fudan University and the Graduate School of Medicine at the University of Tokyo, Japan, where he ultimately earned his doctor's degree in Biostatistics and Epidemiology.

Before joining Elixir Clinical Research, Dr. Tao Wang worked at Pfizer in his early career, where he supported dozens of early-phase clinical trials as a Senior Manager, including products such as JAK3 inhibitor and CDK4/6 marketed for the first indication or subsequent expanded indications. Subsequently, Dr. Tao Wang joined Hengrui, serving as the Head and General Manager of the Clinical Statistics and Programming Department. He led his team in building the statistics and programming team from scratch and provided full lifecycle statistical and programming support for approximately 250 clinical trials across nearly 100 products, aiding the successful market introduction of nearly 10 products for over 20 indications.

Prior to entering the field of pharmaceutical R&D, Dr. Tao Wang served as an assistant professor at the School of Public Health, Fudan University. He has published over ten academic papers and participated in the compilation of several professional books.

Dr. Tao Wang has also focused on important topics such as the scheme design of dose escalation/optimization in early trials, adaptive clinical trial design, and the application of artificial intelligence in pharmaceutical R&D. His expertise and research background are set to bring significant driving force and innovative spirit to the team of Elixir Clinical Research.

Dr. Jie Chen, Chief Scientific Officer and General Manager of Department of Data Science and Pharmacovigilance at Elixir Clinical Research, said:

"Dr. Tao Wang possesses exceptional and profound expertise in the field of biostatistics, and his years of accumulated experience in drug development have endowed him with deep insights in this area. In terms of team management, his strategic thinking and comprehensive perspective highlight his leadership. I firmly believe that Dr. Tao Wang's joining will infuse new vitality and possibilities into Elixir Clinical Research and will strengthen our confidence in providing top-tier data science and related services for clinical research, thus further enhancing our professional advantages and elevating our service level."

Dr. Tao Wang said:

"I am honored to join Elixir Clinical Research and to expand my journey in pharmaceutical R&D under the leadership of Dr. Jie Chen. Elixir Clinical Research is a technology-driven, full-service clinical CRO with comprehensive functional capabilities, a complete process system, and advanced service concepts. The company focuses on establishing close strategic partnerships with clients. Leveraging the strong digital operation platform of the life sciences industry from our parent company, Taimei Technology, along with our rich talent resources and optimized process configurations, we provide efficient, high-quality, and full-lifecycle clinical research services. Here, I look forward to utilizing my expertise and experience to fully enhance the success rate of drug development and achieve our ultimate goal."

For more details, please contact 

info@ecr-global.com